Apimeds Pharmaceuticals US Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of APUS?
Owner Type	Number of Shares	Ownership Percentage
Institutions	200,000	1.73%
Private Companies	840,962	7.27%
Individual Insiders	1,215,385	10.5%
General Public	3,403,268	29.4%
Public Companies	5,911,882	51.1%

Dilution of Shares: APUS only recently listed within the past 12 months

Top Shareholders

Top 6 shareholders own 70.59% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
51.1%	Inscobee., Inc.	5,911,882	US$13.0m	160%	no data
6.91%	Dominus IB, Inc.	800,000	US$1.8m	160%	no data
5.32%	Jakap Koo	615,385	US$1.4m	160%	no data
5.19%	Hyoung Jin Son	600,000	US$1.3m	160%	no data
1.73%	Busan Equity Partners Co., Ltd.	200,000	US$440.0k	0%	no data
0.35%	Jan Partners & Company	40,962	US$90.1k	0%	no data

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/12 12:03
End of Day Share Price	2025/05/12 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Apimeds Pharmaceuticals US, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.